Paces Ferry Wealth Advisors LLC Makes New Investment in Geron Co. (NASDAQ:GERN)

Paces Ferry Wealth Advisors LLC acquired a new stake in Geron Co. (NASDAQ:GERN) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 23,500 shares of the biopharmaceutical company’s stock, valued at approximately $83,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in Geron during the 4th quarter worth approximately $28,000. Readystate Asset Management LP bought a new position in Geron during the 3rd quarter valued at $58,000. Rovin Capital UT ADV increased its position in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,660 shares during the last quarter. Monterey Private Wealth Inc. acquired a new stake in shares of Geron in the 4th quarter valued at about $63,000. Finally, Empowered Funds LLC acquired a new stake in shares of Geron in the 3rd quarter valued at about $67,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Geron in a report on Wednesday, March 12th. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and dropped their price target for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Barclays reissued an “overweight” rating and set a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.75.

Geron Trading Up 4.0 %

Shares of GERN stock opened at $1.82 on Friday. Geron Co. has a 1 year low of $1.46 and a 1 year high of $5.34. The firm has a market capitalization of $1.16 billion, a PE ratio of -5.69 and a beta of 0.53. The stock has a fifty day moving average of $2.42 and a two-hundred day moving average of $3.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. As a group, research analysts expect that Geron Co. will post -0.25 EPS for the current year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.